Insight Molecular Diagnostics Inc. Common Stock IMDX Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 51.3%-3.0pp | 57%+12.9pp | 55.2%— | 55.5%— | 54.3%— | |
| Operating margin | -2,500.7%-977pp | -1,260.8%+1,984pp | -1,392.9%+4,756pp | -1,498.3%+2,079pp | -1,524.1%+1,389pp | |
| Net margin | -2,454.6%-940pp | -1,238.5%+1,987pp | -1,380.7%+4,704pp | -1,489.7%+2,043pp | -1,514.6%+1,376pp | |
| Efficiency | ||||||
| Asset turnover | 0×0.0× | 0.1×+0.1× | 0.1×+0.1× | 0.1×+0.1× | 0.1×0.0× | |
| Liquidity | ||||||
| Current ratio | 2.5×-1.2× | 1.3×-0.3× | 2.8×+2.3× | 4×+2.7× | 3.7×+3.0× | |
| Per Share | ||||||
| Book value per share | -$0.31-178% | -$1.03-9.9% | -$0.29-141% | $0.03-98.1% | $0.40-71.6% | |
| Valuation | ||||||
| Market capitalization | $185.35M+92.3% | $214.98M— | $95.02M— | $98.67M— | —— | |
| Price / sales | 95.1×+72.5× | 53×— | 21.6×— | 23.2×— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Insight Molecular Diagnostics Inc. Common Stock's profit margins?
- Insight Molecular Diagnostics Inc. Common Stock (IMDX) runs a 51.3% gross margin and a -2500.7% operating margin, with a -2454.6% net margin.
- Where do Insight Molecular Diagnostics Inc. Common Stock's ratios come from?
- Every ratio is computed from Insight Molecular Diagnostics Inc. Common Stock's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
